SCHEDULE 14A INFORMATION Proxy Statement Pursuant To Section 14(a) Of The Securities Exchange Act Of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [_] Check the appropriate box: [_] Preliminary Proxy Statement [_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) [_] Definitive Proxy Statement [X] Definitive Additional Materials [_] Soliciting Material Pursuant to Section 240.14a-12 ICN Pharmaceuticals, Inc. -------------------------------------------------------- (Name of Registrant as Specified in its Charter) N/A -------------------------------------------------------- (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): [X] No fee required. [_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: ------------------------------------------------------------------- (2) Aggregate number of securities to which transaction applies: ------------------------------------------------------------------- (4) Proposed maximum aggregate value of transaction: ------------------------------------------------------------------- (5) Total fee paid: ------------------------------------------------------------------- [_] Fee paid previously with preliminary materials. [_] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: ------------------------------------------------------------------- (2) Form, Schedule or Registration Statement No.: ------------------------------------------------------------------- (3) Filing Party: ------------------------------------------------------------------- (4) Date Filed: ------------------------------------------------------------------- Following is the text of an advertisement by ICN on May 29, 2001: This is ICN Creating Value Through Performance [Graphic omitted of man at finish line] Financial Growth [1,3]REVENUES [BAR GRAPH OMITTED - 1995 $273 1996 $347 1997 $627 1998 $696 1999 $747 2000 $800] Compounded Growth 24% 6 years of Record Revenues [3]DIVIDENDS [BAR GRAPH OMITTED - 1995 $0.29 1996 $0.28 1997 $0.24 1998 $0.21 1999 $0.20 2000 $0.19] Compounded Growth 9% [1,3]OPERATING INCOME [BAR GRAPH OMITTED - 1995 $47 1996 $43 1997 $65 1998 $121 1999 $199 2000 $184] Compounded Growth 31% 1 Excludes Yugoslavia. 2 Excludes Eastern European charges, including losses incurred in Yugoslavia in the second quarter of 1998, losses incurred in the third quarter of 1998, relaxed to the Russian economic crisis, and the write-off of ICN Yugoslavia. 3 Charts not to scale. * Cumulative returns based on the stock price as of close of business 12/29/00 excluding dividend reinvestment source Bloomber. Performance...Reaching New Heights ----------- Record Performance Record 2000 revenues of $800 million...another record year Growing Royalty Stream 2000 Ribavirin royalties grew 42% to $155 million Increased R&D Investment Focused on new drug discoveries Strong Stock Performance One Year Return* Five Year Return* Ten Year Return* 21% 59% 967% ICN stockholders are strongly advised to read the proxy statement relating to ICN's 2001 annual meting of stockhholders, as it contains important information Stockholders can obtain this proxy statement, any amendments to the proxy statement and other documents filed by ICN with the Securities and Exchange Commission without charge at the Internet website maintained by the Securities and Exchange Commission at www.sec.gov. In addition, ICN has mailed the proxy statement to each stockholder of record on the record date established for the stockholders meeting. ICN will also make additional copies of the proxy statement and any amendments to the proxy statement available without charge to ICN's stockholders. Please direct your request for the proxy statement to Investor Relations, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa Mesa, California 92626, telephone (714) 545-0100, extension 3104 or to Georgeson Shareholder at (800)-223-2064. Vote the White ICN Proxy card today. [LOGO - ICN] To vote your proxy via fax (toll-free) 1-877-260-0406. For shares held in bank or broker name call Georgeson Shareholder ICN Pharmaceuticals, Inc. 1-800-223-2064 for instructions.